Key result
Etripamil nasal spray secures approval to treat periodic paroxysmal supraventricular tachycardia.
Etripamil nasal spray has been approved for the immediate treatment of periodic paroxysmal supraventricular tachycardia.
Answers are grounded in this paper and cite their sources.
Enables self-administered acute PSVT treatment; extends options beyond IV therapy and confirms nasal CCB efficacy.
The calcium channel blocker etripamil (Cardamyst), a nasal spray, has been approved for treatment of periodic paroxysmal supraventricular tachycardia (PSVT). Nurses should teach patients to treat symptoms of PSVT with etripamil immediately, and how to administer the nasal spray dosage.
No takes yet. Share an insight, caveat, or question.
Diane S. Aschenbrenner (2026) studied this question. Etripamil, a calcium channel blocker nasal spray, has been approved for the treatment of periodic paroxysmal supraventricular tachycardia.
Synapse has enriched 10 related papers. Consider them for comparative context: